Inspections - Good Clinical Practice
GCP Inspectors Working Group
The Sector draws on the expertise of member states’ inspectorates for the fulfilment of many of its GCP related tasks. This is primarily achieved through the GCP Inspectors Working Group.
The GCP Inspectors Working Group focuses on harmonisation and co-ordination of GCP related activities at Community level. The Group activities are outlined in its work plan. It is involved in the preparation of new and revised guidance on GCP and community procedures relating to inspection. The Sector chairs and provides secretarial support to the GCP Inspectors Working Group. Members provide the expertise for the fulfillment of the group tasks and play a key role in the development of collaborative projects both within the community and externally.
The GCP Inspectors Working Group meets on a regular basis four times a year, at EMEA with representatives of the GCP inspectorates of the European Economic Area Member States, observers from candidate countries and Switzerland.
They support the co-ordination of the provision of GCP advice and provide a link with other groups such as CHMP, CVMP, EWP and PhVWP. These links include joint meetings with clinical and pharmacovigilance assessors and contributions to training of both inspectors and assessors. The Mandate of the GCP Inspectors Working Group describes the group's role and activities in more detail.
The GCP Inspectors maintain a dialogue with GMP Inspectors on areas of common interest in particular the interface between GMP for investigational medicinal products and GCP. A GCP / GMP subgroup assists in the interpretation of GMP in a number of specified areas (see workplan).
Documents of Interest:
- Annual report for GCP IWG: 2008
- Workplan for Ad Hoc GCP IWG: 2008, 2009, 2010
- Draft Reflection Paper on Expectations for Electronic Source Documents used in Clinical trials - Released for consultation until 31 April 2008.
- Mandate of the GCP Inspectors Working Group
- Paper on advice to applicants, sponsors, CROs of Bioequivalence Studies - . Many bioequivalence studies are well conducted, however, in recent years a number of cases, (including 3 referred to CHMP), have raised concerns amongst regulators leading to the preparation of this reflection paper.
Send all queries regarding this content to: gcp@ema.europa.eu

RSS feed